BBBeth M. Beadle

Beth M. Beadle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Beth M. Beadle has a total of 487 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Redesigning residency training with artificial intelligence: Implications for efficiency, quality, and workforce capacity

    by Laurence E Court, Beth Beadle, Comron J Hassanzadeh, Skylar S Gay, Tucker J Netherton, Rebecca M Howell, Adam D Melancon

    Purpose: Workforce shortages and increasing clinical demands in Radiation Oncology and Medical Physics present challenges for maintaining high‐quality residency training. This work presents a conceptual framework to evaluate the potential role of artificial intelligence (AI) in improving efficiency, scalability, and quality of residency education. Methods: Current teaching and learning modalities were categorized, and their relative contributions to training were estimated. Potential AI applications were mapped to these modalities, and the proportion of training that could be supported by AI was assessed. A simple conceptual model incorporating training time, AI‐deliverable components (i.e., those potentially supported through direct interaction with AI systems), and dependence on direct human teaching was used to illustrate the potential impact on instructional effort. The potential effect of AI on educational quality was qualitatively evaluated, as well as limitations of AI for routine educational integration. Results: AI applications were identified across multiple domains, including workflow‐integrated feedback, simulation‐based training, adaptive learning, and automated assessment. The largest potential impact was estimated in workflow‐integrated, simulation‐based, and self‐directed learning environments. While reductions in direct human teaching effort were estimated to be modest, AI‐enabled approaches were estimated to achieve substantial improvements in training quality, including increased feedback frequency, enhanced support for deliberate practice, and greater exposure to rare or high‐risk scenarios. Conclusions: AI has the potential to enhance residency training by improving consistency, scalability, and educational quality. In the context of workforce constraints, the primary benefit of AI may be to augment training efficiency and reduce reliance on limited faculty resources while preserving the essential role of clinical experience.

  • Open Access

    Artificial Intelligence–Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning With the Radiation Planning Assistant

    by Tucker J. Netherton, Ajay Aggarwal, Qusai Alakayleh, Beth M. Beadle, Chloe Brooks, Henriette Burger, Carlos E. Cardenas, Adrian Celaya, Sarah Chacko, Christine V. Chung, et al.

    PURPOSE: Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps that can contribute to treatment delays and interobserver variability. The Radiation Planning Assistant (RPA) is a Web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, artificial intelligence–driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries. MATERIALS AND METHODS: We developed deep learning–based auto-contouring models using nnU-Net and integrated them with knowledge-based planning models trained on curated data sets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. RESULTS: In all, 50 test patients (40 prostate, 10 cervical) were evaluated end-to-end. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. CONCLUSION: We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA's infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability.


  • Top Cited Papers

    Systemic Treatment of Thyroid Cancer: ASCO Guideline

    by Nabil F. Saba, Nofisat Ismaila, Douglas Adkins, Nishant Agrawal, Neil Akhave, Erik S. Blomain, Maria E. Cabanillas, Amy Chen, Thomas J. Galloway, Guilherme Harada, et al.

    ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. METHODS: The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: A total of 66 publications were identified to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer. Additional information is available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer .


  • ASO Visual Abstract: Key Updates on the Version 9 AJCC/UICC Staging System for Salivary Gland Carcinoma

    by Shao Hui Huang, Raja R. Seethala, Snehal G. Patel, Brian O’SUllivan, William Lydiatt, Allen S. Ho, Ali Hosni, Vincent Vander Poorten, Christine M. Glastonbury, Justin Bishop, et al.


  • Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience

    by Luana G Sousa, James Edward Bates, Payal Anand, Jimmy J Caudell, A Dimitrios Colevas, Christina L Runge, Jeffrey D Sharon, Musaddiq Awan, Beth M Beadle, Jennifer H Choe, et al.

    Background: Cisplatin remains the cornerstone radiosensitizer for definitive and adjuvant chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. However, despite decades of clinical use, many practical aspects of cisplatin administration remain unstandardized in clinical practice and trials. Methods: Drawing on the collective experience of the NRG Oncology Head and Neck Working Group, this consensus article provides practical guidance on the administration of cisplatin during radiation therapy. We review and propose recommendations regarding the timing of chemotherapy and radiation initiation, premedication and hydration regimens by dose, monitoring and grading of cisplatin-induced ototoxicity, and management strategies during cisplatin shortages. Our guidance is informed by clinical trial protocols, retrospective and prospective data, and multidisciplinary expert consensus. We emphasize the importance of protocol flexibility to support equitable trial accrual, minimize treatment delays, and improve patient-centered outcomes. Conclusions: This article offers a unified framework to optimize the use of cisplatin in chemoradiation protocols, improve adherence, reduce toxicity, and preserve oncologic efficacy. Our recommendations are particularly timely in the context of evolving clinical practices and recent cisplatin shortages. Insights from the NRG Oncology collaborative group aim to inform future trial designs and clinical practice guidelines, ensuring consistent and equitable care for patients with head and neck cancer.


  • Open Access

    Intentional creation of suboptimal, realistic dose distributions

    by Skylar S. Gay, Mary P. Gronberg, Raymond Mumme, Beth M. Beadle, Anuja Jhingran, Tze Yee Lim, Zhiqian H. Yu, Christine Chung, Meena Khan, Chelsea Pinnix, et al.

    Background: Radiation oncology residents report a lack of understanding and confidence in assessing radiotherapy plan quality. A contributing factor is the environment in which plan review is taught during residency, that is, routine clinical practice, which does not provide ample time for self‐guided practice in a low‐stakes setting. Expertise in plan review requires diverse case presentation and many examples, which are often not achievable in smaller programs and for less common cancer types. As plan quality affects patient outcomes, it is important to address these pitfalls in the education of residents on plan review. Purpose: To address the identified pitfalls of clinic‐based training, we have developed techniques to create realistic dose distributions that appear suboptimal in a controllable way. These plans can provide many more case examples in the training curriculum and present a low‐stakes technique for safe and effective education of radiation oncology residents. Methods: High‐quality dose distributions were first generated with a pre‐trained deep learning model (trained using only high‐quality plans). The dose distributions were then altered directly to create three classes of suboptimal dose distributions: (1) decreased organ‐at‐risk sparing, (2) decreased target conformality, and (3) hotspots in the target. Experienced clinicians then reviewed a subset of these suboptimal dose distributions to assess realism. Results: We successfully decreased the quality of radiotherapy dose distributions. The decreased organ‐at‐risk sparing, decreased target conformality, and increased target hotspots were statistically significant ( p < 0.05) when assessed by dose‐volume histogram metrics for all parameters evaluated, and the magnitude of dose change was controllable. The resulting dose distributions were overall scored by experienced clinicians as realistic. Conclusion: In this study, we developed techniques to generate realistic but suboptimal dose distributions. The techniques operate directly on existing dose distributions without the need for a treatment planning system and produce dose distributions that appear realistic to experienced clinicians.

  • Open Access

    AI-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning with the Radiation Planning Assistant (RPA)

    by Tucker J. Netherton, Ajay Aggarwal, Qusai Alakayleh, Beth M. Beadle, Chloe Brooks, Henriette Burger, Carlos E. Cardenas, Adrian Celaya, Sara Chacko, Christine Chung, et al.

    Purpose Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps and clinical hand-offs that contribute to treatment delays and inter-observer variability. The Radiation Planning Assistant (RPA) is a web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, AI-driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries (LMICs). Methods We developed deep learning-based auto-contouring models using nnU-Net and integrated them with knowledge-based planning (KBP) models trained on curated datasets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. Results In total, 50 test patients (40 prostate, 10 cervical) were evaluated. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. Conclusion We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA’s infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability. By reducing reliance on specialist input, this work addresses key barriers to equitable radiotherapy access in resource-limited settings and responds to global calls from the IAEA and WHO to expand radiotherapy capacity. Funding National Institute of Health, National Science Foundation, Rising Tide Foundation, University of Texas MD Anderson Cancer Center


  • Perceptions and Use of Medical Cannabis in Patients with Head and Neck Cancer

    by Jennifer S. Chiang, Jennifer Bs Hall, Sara Richter, Scott Jackson, Vera Ba Qu, Erqi Pollom, Beth M. Beadle

    Objectives: A survey was conducted to evaluate perceptions, use, and information sources of medical cannabis (MC) among patients with head and neck cancer and identify opportunities for providers to clarify its use. Methods: Two hundred eighty-nine consecutive patients with head and neck cancer seen in the radiation oncology department at a single institution in CA (October 2022 to June 2023; November 2023 to January 2024) were screened for eligibility and invited to participate. Surveys were emailed. Demographic/clinical data were collected and recorded from the electronic health record and surveys, including age, gender, race, ethnicity, metastatic status, COVID-19 vaccination status, substance use history, relationship and employment status, and education level. Associations between clinical/socioeconomic factors and perception/use of MC were analyzed using χ 2 tests. Results: Of 258 eligible patients, 122 completed the survey. Most reported reliance on the internet for MC information (70%); only 20% reported consulting with their cancer treatment team. Most (75%) agreed MC can help reduce cancer-related symptoms. Some agreed or were neutral regarding the potential of MC to cure cancer (37%) or prolong life (61%). Overall, 61% of patients reported having used MC, primarily for recreation (72%) or symptom relief (37%). MC use was more common among white ( P =0.001), unmarried ( P =0.001), and tobacco-using individuals ( P =0.045). COVID-vaccinated individuals more often believed MC reduces symptoms ( P =0.015). Conclusion: Many patients rely on unregulated sources regarding MC. This highlights the potential for improved provider-patient discussions to support informed decision-making regarding risks, benefits, and questions of MC in cancer care.